CERCHIONE, CLAUDIO
 Distribuzione geografica
Continente #
NA - Nord America 483
EU - Europa 247
AS - Asia 129
SA - Sud America 1
Totale 860
Nazione #
US - Stati Uniti d'America 477
IT - Italia 136
CN - Cina 79
NL - Olanda 51
VN - Vietnam 44
IE - Irlanda 26
FI - Finlandia 9
SE - Svezia 9
CA - Canada 5
FR - Francia 5
CZ - Repubblica Ceca 3
DE - Germania 3
JP - Giappone 3
GB - Regno Unito 2
IN - India 2
UA - Ucraina 2
CL - Cile 1
HR - Croazia 1
IR - Iran 1
MX - Messico 1
Totale 860
Città #
Chandler 110
Amsterdam 50
Dong Ket 44
Beijing 36
Ashburn 35
Millbury 30
Des Moines 22
Napoli 22
Princeton 18
Naples 16
Nanjing 14
Lawrence 10
Boston 9
Dublin 6
Marcianise 5
Norwalk 5
Ottawa 5
Gesualdo 4
Luzzano 4
Nanchang 4
Wilmington 4
Changsha 3
Jiaxing 3
Kunming 3
Milan 3
Nocera Inferiore 3
Redwood City 3
Shenyang 3
Genova 2
Giugliano In Campania 2
Guangzhou 2
Hebei 2
Marano 2
Marigliano 2
Rome 2
Sarno 2
Seattle 2
Tokyo 2
Avigliano 1
Bologna 1
Campagna 1
Como 1
Dearborn 1
Eindhoven 1
Fairfield 1
Foggia 1
Hanover 1
Indiana 1
London 1
Mestre 1
Mexico 1
Mondragone 1
Mountain View 1
Nanning 1
Otterbäcken 1
Portici 1
Richland 1
Shanghai 1
Shenzhen 1
Siracusa 1
Sorano 1
Tianjin 1
Torre Annunziata 1
Trento 1
Venezia 1
Washington 1
Woodbridge 1
Zagreb 1
Zhengzhou 1
Totale 525
Nome #
RISPOSTA EMATOLOGICA AL TRATTAMENTO CON LENALIDOMIDE IN UNA PAZIENTE AFFETTA DA TROMBOCITEMIA ESSENZIALE JAK2 V617F-POSITIVA E SINDROME MIELODISPLASTICA ASSOCIATA A DEL(5Q) 55
A Frontline Approach With Peripherally Inserted Versus Centrally Inserted Central Venous Catheters for Remission Induction Chemotherapy Phase of Acute Myeloid Leukemia: A Randomized Comparison 54
An 1H NMR study of the cytarabine degradation in clinical conditions to avoid drug waste, decrease therapy costs and improve patient compliance in acute leukemia 50
Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience 49
Secondary syphilis mimicking malignancy: A case report and review of literature 47
Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma 44
Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: A real-life experience 44
Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1,3-β-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography 44
Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience 40
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis 38
Pegfilgrastim in primary prophylaxis of febrile neutropenia in elderly patients with hematological malignancies—bendamustine and G-CSF support 38
Myeloma and other monoclonal gammopathies - Clinical SINONASAL EXTRAMEDULLARY PLASMACYTOMA: PROPOSAL OF PROTOCOL OF FOLLOW-UP 37
Randomized comparison of power Doppler ultrasonography-guided core-needle biopsy with open surgical biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma 36
A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide 32
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease 31
Safety and comfort of domestic bortezomib injection in real-life experience 31
Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial 31
Managing neutropenia by pegfilgrastim in patients affected by relapsed/refractory multiple myeloma treated with bendamustine-bortezomib-dexamethasone 29
Vitiligo-like lesions in an adult patient treated with Imatinib mesylate 25
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma 25
Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report 25
Reply to the letter to the editor "chronic disseminated candidiasis" by Kenneth Rolston 24
Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia 24
Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis 22
KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients 22
Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma. Eur J Haematol 2020; 105: 667-671." 21
Is anticoagulation with novel oral anticoagulants an effective treatment for tuberculosis patients not achieving a therapeutic range with vitamin k antagonists? A Systematic Review 20
PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial 17
Randomized Comparison of Power Doppler Ultrasonography-Guided Core-Needle Biopsy with Open Surgical Biopsy for the Characterization of Lymphadenopathies in Patients with Suspected Lymphoma, 10
Totale 965
Categoria #
all - tutte 2.973
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.973


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201956 0 0 0 0 0 9 6 25 1 7 3 5
2019/2020130 36 2 7 4 5 3 2 5 3 38 18 7
2020/202189 6 0 3 1 14 8 0 7 0 3 0 47
2021/2022205 0 0 0 0 1 10 5 5 21 17 82 64
2022/2023287 28 14 15 10 37 28 2 34 47 52 17 3
2023/202487 8 25 14 9 18 13 0 0 0 0 0 0
Totale 965